Immediate invasive strategy in high-risk non-ST-segment elevation acute coronary syndrome: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068993

Enrollment

Unknown

Registered

2023-03-03

Start date

2023-03-15

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS)

Interventions

Immediate-intervention group:Patients in the immediate-intervention group were transferred for angiography as soon as possible but no later than 2 h after randomization

Early invasive strategy group:Patients underwent invasive intervention between 2-24 h of randomization.

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: High-risk NSTE-ACS patients aged >=20 years, defined in the ESC NSTE-ACS Guidelines 2020 as having typical ischemic chest pain symptoms, and having at least one of the following high-risk criteria: 1. NSTEMI was diagnosed; 2. The dynamic change of ST/T or the continuous change of ST/T indicates that the patient is still in ischemia state; 3. Transient ST elevation; 4. GRACE risk score >140.

Exclusion criteria

Exclusion criteria: Hemodynamic instability, electrical instability, cardiogenic shock and very highly-risk NSTE-ACS patients.

Design outcomes

Primary

Measure	Time frame
Major cardiac adverse events, MACE;	—

Secondary

Measure	Time frame
Length of stay, myocardial infarct size, cardiac function;Major bleeding, unplanned revascularization and ischemia stroke;	—

Countries

China

Contacts

Public ContactLiu Haibo

Qingpu Branch of Zhongshan Hospital, Fudan University

haiboliu13@fudan.edu.cn+86 189 6492 0596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026